SUMMARY A double blind cross over study was performed to compare the long term hormonal, haemodynamic, and clinical responses to specific inhibition of the renin-angiotensin-aldosterone system (captopril) and of the oa adrenoceptors of the sympathetic system (prazosin) both at rest and during upright exercise in patients with chronic heart failure. Sixteen patients completed one month's treatment with each drug.
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importance of these neuroendocrine systems in heart failure in animals5 and man6 -8 at rest, but there has been no controlled study of relations between hormonal changes, haemodynamic measurements, and clinical features on exercise during long term treatment of heart failure.
A double blind, randomised crossover trial was undertaken to compare the long term hormonal, haemodynamic, and clinical responses to specific inhibition of the renin-angiotensin-aldosterone system (with captopril) and of the a, adrenoceptors of the sympathetic system (with prazosin) both at rest and during upright exercise in patients with chronic heart failure. The results of changes occurring at rest in this study have been reported elsewhere.9
Patients and methods
We studied 16 patients (15 men) (mean age 62 years, range 48 to 74 years). All patients had been in heart failure for at least 3 months. The aetiology of heart failure was coronary artery disease without recent myocardial infarction in 10 patients and dilated cardiomyopathy in six. No patient had important valvar, hypertensive, or renal disease.
All patients were breathless on moderate exertion (New York Heart Association class II-III), with radiologically confirmed pulmonary venous hypertension and cardiomegaly (cardiothoracic ratio > 0 5), despiteoptimal diuretic treatment. Frusemide (mean daily dose 138 mg) was given in combination with amiloride (9 mg). Only the three patients in atrial fibrillation received digoxin for control of ventricular rate. Other vasodilating drugs and spironolactone were not used during the study. All patients gave written informed consent. The study was approved by the hospitals' ethical committees. STUDY 
DESIGN
Patients were observed during a one week control period, while they were on diuretics and placebo, to ensure that they were in a stable clinical state with constant body weight and without peripheral oedema.
Control haemodynamic and hormnonal measurements were then made at rest and during treadmill exercise (see below). Patients were then randomly allocated to treatment and were started on captopril (25 mg eight hourly) or prazosin (2 mg eight hourly). These drugs were given double blind by the double dummy technique and the doses were doubled after one week. The doses chosen have been shown7 to produce similar acute haemodynamic effects, and are often used in clinical practice.
After one month, clinical, haemodynamic, and Plasma renin activity and aldosterone were measured by radioimmunoassay12 13 (normal ranges 0 5-2-5 ng/ml/h (0 39-1-9 nmol/l/h) and 100-600 pmol/l, respectively). We measured plasma noradrenaline by radioenzymatic assay using a modification (P Sever, personal communication) of Henry's method"4 (normal range 200-800 pg/ml (1 24-7 nmol/l)). Plasma vasopressin was measured by radioimmunoassay'5 (normal range: 04-1-6 p units/ml (0-92-3-68 pmol/l)).
PLASMA DRUG CONCENTRATIONS
Plasma captopril was not measured; increasing plasma renin activity was used as an indicator of effective converting enzyme inhibition. Plasma prazosin was measured by high pressure liquid chromatography. 16 
Results
There were no significant changes in any variable during the placebo period or during the control periods before each haemodynamic study.
CLINICAL EFFECTS
While on captopril 15 patients improved symptomatically, reporting a reduction in breathlessness and an increase in exercise capacity and general wellbeing; one patient did not improve. Mean weight fell by 1 6 kg (-3-2, -0-1 p=0 05) after one month, without any increase in diuretic dosage.
On prazosin five patients reported an initial improvement in symptoms, three were unchanged, and eight deteriorated. Peripheral oedema developed in six patients. During the month of treatment mean weight increased by 2-6 kg (+0 4, +4 9 p = 0 03) despite an increase in the frusemide dosage in four patients who developed oedema after one week. Mean weight increased by 1 9 kg (+0 7, +3 1, p =0 04) even in the 10 patients who did not become oedematous.
Mean treadmill exercise time at the end of the placebo period was 17 5 min (12 0, 23 0); exercise was terminated by breathlessness in 11 patients, and by fatigue in five. Captopril increased exercise time by 6 2 min (+3 0, +9 5 p=0-001); four patients who had been limited by breathlessness were now limited by fatigue. Prazosin had no effect on exercise time (+0 7 min, -5 7, +7 0 p=081); eight patients were limited by breathlessness and eight by fatigue. 10(6,14)
Cardiac index (l/minIm2)
Heart rate (beats/lmn) index because, although it increased resting stroke volume index from a control value of 23 ml (20, 26) to 27 (23, 30 p=0 01), it also reduced resting heart rate from 88 beats/min (81, 95) to 80 beats/min (74, 87 p = 003). During exercise on captopril, cardiac index was greater than the corresponding control values, both after six minutes (submaximal exercise, p = 0 01) and at maximal exercise (p = 0 04), because of a greater increase in stroke volume. Ventricular performance therefore improved at rest and on exercise with captopril but not with prazosin ( Fig. 1) .
The control mean blood pressure was normal at rest, and did not change significantly on exercise (p=0-13) (Fig. 2) . Prazosin caused no long term change in blood pressure, either at rest or on exercise. Captopril reduced mean blood pressure at rest (p = 001) but not during exercise.
The mean control systemic vascular resistance was raised at rest, and, although it fell during exercise (p<0-0001), it remained abnormally raised at maximal exercise (Fig. 2) the control or treatment periods (r < 0-37) (Fig. 3) , nor did changes in exercise time with treatment correlate with changes in pulmonary artery end diastolic pressure (Fig. 4) 
RENIN-ANGIOTENSIN-ALDOSTERONE SYS.TEM
Control resting plasma renin activity and aldosterone were normal in four patients, but were raised in the remaining 12 (Table 2) , correlating with resting pulmonary artery end diastolic pressure (r = 0 58, p = 0 02 and r = 0 51, p = 0 04 respectively) and with resting right atrial pressure (r=0-53, p=0 04 and r=0-77, p=0 001), but not with other resting variables (p > 0 24). During exercise, there were pronounced increases in plasma renin activity and aldosterone (p = 0 0002, p <0-0001). Plasma renin activity at maximal exercise correlated with pulmonary artery end diastolic pressure and right atrial pressure at maximal exercise (r=0-61, p=0-01 and r=0-51, p=0 05).
Inhibition of angiotensin converting enzyme with captopril increased plasma renin activity at rest and on exercise (p=0-0006, p=0 02), and reduced plasma aldosterone both at rest and on exercise (p=0 02, p=0 04). During captopril treatment, ventricular filling pressures were unrelated to plasma renin activity or aldosterone.
Inhibition of the a adrenergic sympathetic system with prazosin increased resting plasma aldosterone after one week by 296 pmol/l (+ 150, +441 p = 00009). After one month, however, when fluid retention and circulatory expansion had occurred, rest and exercise values of plasma renin activity and aldosterone were similar to control values, and correlated with ventricular filling pressures (r>05, p <004).
The changes in plasma aldosterone after one week's treatment with captopril and with prazosin correlated with the changes in body weight after one month on each drug (r = 0 48, p = 0 007). In the control period, the exercise induced increase in plasma renin activity correlated inversely with the reduction in systemic vascular resistance on exercise (r= -063, p=O 0009) (Fig. 5) ; those patients with the greatest increase in plasma renin activity had the least vasodilatation on exercise, those with the least renin release achieved the greatest vasodilatation. This relation was no longer seen on captopril and systemic vascular resistance on exercise was lower than control values. On prazosin, the increase in plasma renin activity on exercise still The control resting plasma noradrenaline was normal in five patients, but was raised in the remaining 11 (Table 2) , and did not correlate with any single resting haemodynamic variable. Exercise caused a pronounced increase in plasma noradrenaline in all patients (p < 0 0001). On captopril, resting plasma noradrenaline was reduced (p=0 04). The pattern of increase of noradrenaline during exercise on captopril was similar to that during the control period (even though a greater workload was achieved) and correlated with the exercise induced increase in heart rate (r=0 71, p = 0002).
After one week of prazosin, resting plasma noradrenaline was increased by 371 pg/ml (+ 41, + 702) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) nmol/l: + 0 24, + 4-14) (p = 0 02), but after one month resting and exercise values were similar to control values.
During exercise in the control, captopril, and prazosin periods, the exercise induced increase in noradrenaline correlated inversely with the reduction in systemic vascular resistance on' exercise (r= -0 62 p=0023; r= -067 p=0009; r= -072 p=0003 respectively). Those patients with the greatest increase in noradrenaline tended to have the least reduction 'in total systemic vascular resistance on exercise.
PLASMA VASOPRESSIN
The control resting plasma vasopressin was normal in all but three patients (Table 2) , and did not correlate with plasma sodium or plasma osmolality or any haemodynamic variable. During upright exercise, plasma vasopressin increased in 12 patients (p = 003), but the peak value remained within the physiological range.
Prazosin caused no significant changes in vasopressin at rest or on exercise. During captopril treatment resting vasopressin was unchanged and there was no increase in vasopressin during exercise (p = 0-22) despite the greater workload achieved.
PLASMA PRAZOSIN CONCENTRATIONS
After one month's treatment, mean plasma prazosin concentration was 29-2 ng/ml (18, 41 ) (0-070 mmol/l: 0 043, 0 098) before a maintenance dose, increasing to 40 4 ng/ml (29, 52 ) (0 096 mmol/l: 0-069, 0-124) (t=2 87 p=002) two hours after a 4 mg dose. These drug concentrations are high, despite the relatively low dose of prazosin used, and could have resulted in prazosin inhibiting a2 as well as a, adrenoceptors.
271 Discussion This is the first controlled study of interrelations between neuroendocrine systems, haemodynamic variables, and clinical characteristics both at rest and during upright exercise in the long term treatment of chronic heart failure.
The sympathetic and renin-angiotensin-aldosterone systems are usually activated in chronic heart failure, to maintain blood pressure and perfusion of the cerebral and coronary circulations. ' 20 Renal, splanchnic, and cutaneous vasoconstriction occurs at rest and particularly during exercise, when the limited cardiac output must also supply an increased flow to working muscle. The vasodilatation that occurs in exercising muscle in healthy subjects is almost entirely due to local production of vasodilator metabolites, but in chronic heart failure this vasodilatation is impaired by mechanisms that are poorly understood.20
Homoeostatic neuroendocrine responses may have evolved to maintain the circulation during hypovolaemia and haemorrhage,2 land to some extent they may support a failing circulation in heart failure. Maintained vasoconstriction and fluid retention, however, reduce ventricular performance. To examine the roles of the renin-angiotensinaldosterone and sympathetic systems in circulatory regulation in chronic heart failure, we performed a double blind, randomised cross over study to compare the effects of two neuroendocrine inhibitors, captopril and prazosin.25 26 Captopril, an angiotensin converting enzyme inhibitor, causes vasodilatation by preventing the formation of angiotensin II, and it thus also reduces aldosterone secretion. Prazosin, an a, adrenoceptor inhibitor, has acute vasodilator effects similar to those of captopril,7 and causes venous and arteriolar dilatation by withdrawal of sympathetic activity. We studied only stable patients with mild to moderate heart failure (New York Heart Association class II-III), to permit measurements on exercise, and because in more severely ill patients hormonal abnormalities may be less important determinants of response to treatment than the natural progression of the disease itself.
'Plasma renin activity, aldosterone, and noradrenaline were raised at rest in most patients, and increased further on exercise. It has been suggested that the renin system is activated in acute phases of heart failure but then returns to normal during 272 stable chronic heart failure. 6 We found that the renin system was stimulated in chronic heart failure; it was not even suppressed in the patients who developed circulatory expansion on prazosin. Furthermore, patients who had near normal levels of plasma renin activity, aldosterone, or noradrenaline at rest developed greatly increased levels during exercise.
Several relations between hormonal, haemodynamic, and clinical variables were observed. Control ventricular filling pressures were raised and they correlated with plasma renin activity at rest and on exercise. Left ventricular filling pressures at maximal exercise did not correlate with exercise time, nor did any changes in filling pressures with treatment correlate with changes in exercise time. This lack of correlation between central haemodynamic variables and exercise capacity has been shown in other studies. 27 28 Inhibition of the renin-angiotensin system by captopril reduced aldosterone and facilitated natriuresis, such that weight fell without an increase in diuretic dose. Left ventricular filling pressure fell both at rest and on exercise, and 15 patients reported a reduction in breathlessness. Plasma noradrenaline and heart rate were also reduced at rest on captopril, indicating some withdrawal of sympathetic activity.
Alpha adrenergic inhibition with prazosin caused vasodilatation which was associated with initial stimulation of the renin-angiotensin-aldosterone system and subsequent fluid retention, with oedema developing in six patients. Ventricular filling pressures were not reduced, and breathlessness improved in few patients.
The relation between vasopressin and ventricular filling pressures in heart failure is unclear. In the normal circulation, non-osmotic control reduces vasopressin release when atrial pressures increase, whereas in severe heart failure vasopressin release appears to occur independently of osmotic or nonosmotic control. 29 The patients in this study, with moderate heart failure, may illustrate an intermediate stage in the derangement of vasopressin control, since they had normal vasopressin concentrations at rest and on exercise, but these did not respond appropriately to changes in atrial pressures.
The total systemic vascular resistance in our patients was invariably raised, reflecting vasoconstriction in at least some vascular beds. Relations between vasoconstriction and neuroendocrine systems were studied by assessing the effects of exercise, before and in the presence of captopril and prazosin.
During the control period the reduction in systemic vascular resistance during exercise correlated inversely with increases in plasma renin activity and noradrenaline, suggesting that both angiotensin II Bayliss, Canepa-Anson, Norell, Poole-Wilson, Sutton and adrenergic mechanisms were limiting vasodilatation. Inhibition of a1 adrenoceptors with prazosin resulted in arteriolar vasodilatation at rest; during exercise it might have been expected that prazosin would facilitate vasodilatation by blocking a adrenoceptors and allowing unopposed stimulation of vasodilating fi2 receptors. The reduction in vascular resistance during exercise, however, was no greater than in the control period; it still correlated inversely with renin and noradrenaline release, and exercise capacity did not increase. Exercise capacity in chronic heart failure is related to nutritive muscle blood flow during exercise,30 and is only poorly related to central haemodynamic variables. 27 28 Since prazosin caused vasodilatation at rest, but did not facilitate greater vasodilatation on exercise, or increase exercise capacity, our results can be interpreted as indirect evidence that prazosin did not increase muscle blood flow.
With inhibition of the renin-angiotensin system by captopril, systemic vascular resistance was reduced from control values both at rest and on exercise, even though plasma noradrenaline still increased. The change in systemic vascular resistance on exercise was no longer correlated with the change in plasma renin activity. The improved vasodilatation on exercise was associated with an increased exercise capacity, suggesting there had been an improvement in muscle blood flow. [30] [31] [32] Although hormonal and haemodynamic changes occur immediately after administration of captopril, exercise capacity does not improve immediately, but increases progressively over a period of weeks. 33 Neither the acute changes in angiotensin II nor any acute haemodynamic changes can thus be directly responsible for the changes in exercise capacity. More long term changes in muscle blood flow on exercise are likely to be involved.
It has been suggested that the impairment of maximal vasodilatation in exercising muscle in heart failure is due to a "vascular stiffness factor", possibly related to the sodium content of the blood vessel wall."9 Our study provides indirect evidence that angiotensin II may be such a factor, acting directly or indirectly through its effects on aldosterone and increasing the stiffness and sodium content of the vessel wall.
This study has established the important contribution of neuroendocrine systems in determining the haemodynamic and clinical features of chronic heart failure at rest and during exercise, and illustrates how inhibition of the renin-angiotensinaldosterone system, in particular, can result in long term clinical improvement.
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